0001214659-24-004303.txt : 20240311
0001214659-24-004303.hdr.sgml : 20240311
20240311103507
ACCESSION NUMBER: 0001214659-24-004303
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240307
FILED AS OF DATE: 20240311
DATE AS OF CHANGE: 20240311
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Boyd Peter E.
CENTRAL INDEX KEY: 0001739816
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38599
FILM NUMBER: 24736920
MAIL ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Aquestive Therapeutics, Inc.
CENTRAL INDEX KEY: 0001398733
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 208623253
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
BUSINESS PHONE: 908-941-1900
MAIL ADDRESS:
STREET 1: 30 TECHNOLOGY DRIVE
CITY: WARREN
STATE: NJ
ZIP: 07059
FORMER COMPANY:
FORMER CONFORMED NAME: MonoSol Rx, Inc.
DATE OF NAME CHANGE: 20070507
4
1
marketforms-64689.xml
PRIMARY DOCUMENT
X0508
4
2024-03-07
0001398733
Aquestive Therapeutics, Inc.
AQST
0001739816
Boyd Peter E.
C/O AQUESTIVE THERAPEUTICS, INC.
30 TECHNOLOGY DRIVE
WARREN
NJ
07059
false
true
false
false
See Remark
0
Common Stock
2024-03-07
4
A
false
86250
0
A
245998
D
Non-Qualified Stock Option (right to buy)
5.68
2024-03-07
4
A
false
43125
0
A
2034-03-07
Common Stock
43125
43125
D
The Common Stock is represented by restricted stock which will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
The original Form 4, filed on 3/9/23, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the inclusion of shares for 59,532 shares owned when in fact 59,748 shares of the Issuer's common stock were owned. As a result of this administrative error, the number of shares beneficially owned by the reporting person following the corrected transaction reflects an increase in the number of shares reported as beneficially owned by the reporting person by 216 shares.
The options will vest in three annual installments with 25% on the 1st installment, 25% on the 2nd installment and 50% on the 3rd installment.
SVP, Information Technology, Human Resources and Communications
/s/ Lori Braender, as Attorney-In-Fact
2024-03-11